Aptorum Group Faces Going Concern Warning Amidst Highly Dilutive DiamiR Reverse Merger and Internal Control Weakness

summarizeSummary

Aptorum Group's annual report reveals a going concern warning from its auditor and management, alongside a material weakness in internal financial controls, as it pursues a highly dilutive reverse merger with DiamiR Biosciences that will leave existing shareholders with only 30% ownership of the combined entity.

check_boxKey Events

• Going Concern Warning Issued

  Both management and the independent auditor have expressed substantial doubt about Aptorum Group's ability to continue as a going concern due to recurring net losses of $1.38 million in 2025 and negative working capital of $1.00 million as of December 31, 2025.

• Highly Dilutive Reverse Merger with DiamiR Biosciences

  The company is proceeding with a reverse merger with DiamiR Biosciences, where DiamiR stockholders will own approximately 70% and existing Aptorum shareholders will own 30% of the combined company. This transaction is subject to several closing conditions, including Aptorum maintaining specific cash and working capital levels, which were not met as of December 31, 2025.

• Material Weakness in Internal Controls

  Management identified a material weakness in internal control over financial reporting for the year ended December 31, 2025, attributed to a lack of dedicated resources for finance and accounting functions.

• Significant Capital Raises in 2025

  Aptorum Group completed two registered direct offerings in January and October 2025, raising aggregate gross proceeds of $5.07 million. The October 2025 offering included 2,000,000 restricted warrants, and both offerings were priced at $2.00 per share, significantly above the current stock price of $0.93.

auto_awesomeAnalysis

Aptorum Group's annual report for 2025 highlights severe financial and operational challenges. Both management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern, citing recurring net losses and negative working capital. The company is pursuing a reverse merger with DiamiR Biosciences, a transaction that will result in significant dilution for existing Aptorum shareholders, who are projected to own only 30% of the combined entity. This strategic pivot, which caused a pause in R&D activities, is critical for the company's future but comes with substantial risks, including unmet cash and working capital conditions. Additionally, a material weakness in internal financial reporting controls was identified, further raising governance concerns. These factors collectively present a highly negative outlook for investors.